Background Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor
of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) …

Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …

Hyperlipidemia is a known risk factor for fatty infiltration of the liver, a condition that can
progress to cirrhosis and liver failure. The objectives of this study were to document the …

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and
potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir …

Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …

Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV)
infection as a public health threat by 2030; existing therapies and prophylaxis …

BACKGROUND: Chronic infection with hepatitis C virus (HCV) is a major cause of cirrhosis,
hepatocellular carcinoma and liver transplantation.OBJECTIVE: To estimate the burden of …

Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for chronic
hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF treatment for …

Hepatitis D virus (HDV) infection occurs as a coinfection with hepatitis B and increases the
risk of hepatocellular carcinoma, decompensated cirrhosis, and mortality compared to …

Background: Through 5 years of treatment with tenofovir disoproxil fumarate (TDF) in mostly
naïve patients, we reported sustained viral suppression with regression of fibrosis, and …